Shawn T. Estrem
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, TGF-β signaling in diseases, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Genome of the Bacterium Streptococcus pneumoniae Strain R6(2001)735 cited
- → Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway(2015)539 cited
- → Identification of an UP element consensus sequence for bacterial promoters(1998)302 cited
- → Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer(2018)267 cited
- → Transcriptome signature of resistance exercise adaptations: mixed muscle and fiber type specific profiles in young and old adults(2012)262 cited
- → First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma(2014)230 cited
- → Bacterial promoter architecture: subsite structure of UP elements and interactions with the carboxy-terminal domain of the RNA polymerase alpha subunit(1999)209 cited
- → Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma(2012)204 cited
- → Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer(2021)184 cited
- → Promoter recognition and discrimination by EσS RNA polymerase(2001)169 cited